跳至主要内容
临床试验/EUCTR2021-001520-18-NL
EUCTR2021-001520-18-NL进行中(未招募)1 期

ong term efficacy and safety of SARS-CoV-2 vaccination in Dutch patients with chronic kidney disease stage G4-G5, on dialysis or after kidney transplantation - The LESS CoV-2 study

RECOVAC consortium0 个研究点目标入组 24,300 人开始时间: 2021年3月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
24,300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1.Eligible for COVID-19 vaccination as described by the instructions of the manufacturer.
  • 2.Age of 18 years or older
  • 3.Capable of understanding the purpose and risks of the study, fully informed and given written informed consent (signed informed consent form has been obtained)
  • -eGFR < 30 ml/min/1.73m2 but not on dialysis or with a kidney transplant
  • -Hemodialysis, or peritoneal dialysis
  • -Kidney Transplant recipient at least 6 weeks after transplantation
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 8000
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 4000

排除标准

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s).
  • Patients who opted out for research in the Santeon, RENINE and NOTR registries.
  • Patients who participate in the RECOVAC-IR study.

研究者

发起方
RECOVAC consortium

相似试验

ong term efficacy and safety of COVID-19 vaccination... | 临床试验